Bioactive lipids and their receptors

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 728-740

  Angel, Itzchak ^a   Bar, Adina ^a   Haring, Rachel ^a  

^a D Pharm Ltd   (Israel)

Author keywords

Endothelial differentiation gene receptors; G protein coupled receptors; Lipid metabolism; Lysophosphatidic acid; Sphingosine 1 phosphate

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CERAMIDE; DRONABINOL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; GLYCEROLIPID; IMMUNOSUPPRESSIVE AGENT; IODINE 125; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTAGLANDIN; PROSTAGLANDIN RECEPTOR; PROTEIN KINASE C; PSYCHOSINE; RECEPTOR SUBTYPE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSYLPHOSPHORYLCHOLINE; THROMBOCYTE ACTIVATING FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNITY; BINDING AFFINITY; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; LIGAND BINDING; LIPID METABOLISM; MOUSE; NONHUMAN; OVARY CANCER; RECEPTOR BINDING; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE;

ANIMALS; HUMANS; LIPIDS; PROSTAGLANDINS; RECEPTORS, DRUG; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 0036771209     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Goetzl EJ, An S: Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J (1998) 12:1589-1598.
2. Koval M, Pagano RE: Intracellular transport and metabolism of sphingomyelin. Biochim Biophys Acta (1991) 1082:113-125.
3. Tabas I: Secretory sphingomyelinase. Chem Phys Lipids (1999) 102:123-130.
4. Spiegel S, Merrill AH Jr: Sphingolipid metabolism and cell growth regulation. FASEB J (1996) 10:1388-1397.
5. Spiegel S, Milstien S: Functions of a new family of sphingosine-1-phosphate receptors. Biochim Biophys Acta (2000) 1484:107-116.
6. Huwilera A, Kolterb T, Pfeilschiftera J, Sandhoffb K: Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta (2000) 1485:63-99.
7. Hannun YA, Obeid LM: The ceramide-centric universe of lipid-mediated cell regulation: Stress encounters of the lipid kind. J Biol Chem (2002) 277:25847-25850.
8. Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kronke M: TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced 'acidic' sphingomyelin breakdown. Cell (1992) 71:765-776.
9. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science (1996) 274:1855-1859.
10. Dobrowsky RT, Wemer MH, Castellino AM, Chao MV, Hannun YA: Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. Science (1994) 265:1596-1599.
11. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M: Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell (1994) 78:1005-1015.
12. Brenner B, Koppenhoefer U, Weinstock C, Linderkamp O, Lang F, Gulbins E: Fas- or ceramide-induced apoptosis is mediated by a Racl-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem (1997) 272:22173-22181.
13. Kleine L, Liu G, Leblanc N, Hebert RL: Bradykinin stimulates ceramide production by activating specific BKB, receptor in rat small artery. Am J Physiol - Heart Circulatory Physiology (2002) 282:H175-H183.
14. Hannun YA, Bell RM: Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science (1989) 243:500-507.
15. Yatomi Y, Ruan F, Hakomori S, Igarashi Y: Sphingosine-1-phosphate: A platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood (1995) 86:193-202.
16. Olivera A, Spiegel S: Sphingosine kinase: A mediator of vital cellular functions. Prostaglandins (2001) 64:123-134.
17. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S: Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem (1998) 273:23722-23728.
18. Kupperman E, An S, Osborne N, Waldron S, Stainier DY: A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. Nature (2000) 406:192-195.
19. Pyne S, Pyne NJ: Sphingosine 1-phosphate signalling in mammalian cells. Biochem J (2000) 349:385-402.
20. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ: Lysophospholipids - receptor revelations. Science (2001) 294:1875-1878.
21. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T: Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem (2002) 50:661-670.
22. Ryu Y, Takuwa N, Sugimoto N, Sakurada S, Usui S, Okamoto H, Matsui O, Takuwa Y: Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res (2002) 90:325-332.
23. Banno Y, Takuwa Y, Akao Y, Okamoto H, Osawa Y, Naganawa T, Nakashima S, Suh PG, Nozawa Y: Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3. J Biol Chem (2001) 276:35622-35628.
24. Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J: Lysophospholipid receptors. Annu Rev Pharmacol Toxicol (2001) 41:507-534.
25. Boguslawski G, Grogg JR, Welch Z, Ciechanowicz S, Silva D, Kovala AT, McGlynn P, Brindley DN, Rhoades RA, English D: Migration of vascular smooth muscle cells induced by sphingosine 1-phosphate and related lipids: Potential role in the angiogenic response. Exp Cell Res (2002) 274:264-274. SIP may play a role in angiogenesis by coordinating the migration of both endothelial cells and VSMC in response to changing gradients of bioactive lipids.
26. Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, Walsh K, Hla T, Sessa WC: Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a G, protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem (2001) 276:19672-19677.
27. Igarashi J, Bemier SG, Michel T: Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. Differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem (2001) 276:12420-12426.
28. Igarashi J, Michel T: Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase β. Evidence for divergence and convergence of receptorregulated endothelial nitric-oxide synthase signaling pathways. J Biol Chem (2001) 276:36281-36288.
29. 2+ oscillations in cardiac cells. J Cell Biol (2001) 152:717-728.
30. Prasad R, Lavrik O, Kim SJ, Kedar P, Yang XP, Vande Berg BJ, Wilson SH: DNA polymerase β-mediated long patch base excision repair. Poly(ADP-ribose)polymerase-1 stimulates strand displacement DNA synthesis. J Biol Chem (2001) 276:32411-32414.
31. Benaud C, Oberst M, Hobson JP, Spiegel S, Dickson RB, Lin CY: Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem (2002) 277:10539-10546.
32. Rodriguez-Lafrasse C, Vanier MT: Sphingosylphosphorylcholine in Niemann-Pick disease brain: Accumulation in type A but not in type B. Neurochem Res (1999) 24:199-205.
33. Liliom K, Sun G, Bunemann M, Virag T, Nusser N, Baker DL, Wang DA, Fabian MJ, Brandts B, Bender K, Eickel A et al: Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: A possible role in regulating cardiac function via sphingolipid receptors. Biochem J (2001) 355:189-197.
34. Spiegel S, Milstien S: Sphingolipid metabolites: Members of a new class of lipid second messengers. J Membr Biol (1995) 146:225-237. This review exemplifies the role of different metabolites of sphingolipid as second messengers.
35. Xu Y, Zhu K, Hong G, Wu W, Baudhuin LM, Xiao Y, Damron DS: Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol (2000) 2:261-267.
36. Zhu K, Baudhuin LM, Hong G, Williams FS, Cristina KL, Kabarowski JH, Witte ON, Xu Y: Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G proteincoupled receptor GPR4. J Biol Chem (2001) 276:41325-41335.
37. Svennerholm L, Vanier MT, Mansson JE: Krabbe disease: A galactosylsphingosine (psychosine) lipidosis. J Lipid Res (1980) 21:53-64.
38. Im DS, Heise CE, Nguyen T, O'Dowd BF, Lynch KR: Identification of a molecular target of psychosine and its role in globoid cell formation. J Cell Biol (2001) 153:429-434.
39. Choi JW, Lee SY, Choi Y: Identification of a putative G protein-coupled receptor induced during activation-induced apoptosis of T cells. Cell Immunol (1996) 168:78-84.
40. Kanazawa T, Nakamura S, Momoi M, Yamaji T, Takematsu H, Yano H, Sabe H, Yamamoto A, Kawasaki T, Kozutsumi Y: Inhibition of cytokinesis by a lipid metabolite, psychosine. J Cell Biol (2000) 149:943-950.
41. Bulger EM, Maier RV: Lipid mediators in the pathophysiology of critical illness. Crit Care Med (2000) 28:N27-N36.
42. van der Bend RL, de Widt J, van Corven EJ, Moolenaar WH, van Blitterswijk WJ: Metabolic conversion of the biologically active phospholipid, lysophosphatidic acid, in fibroblasts. Biochim Biophys Acta (1992) 1125:110-112.
43. Pages C, Simon M, Valet P, Saulnier-Blache JS: Lysophosphatidic acid synthesis and release(1). Prostaglandins (2001) 64:1-10.
44. Jasinska R, Zhang QX, Pilquil C, Singh I, Xu J, Dewald J, Dillon DA, Berthiaume LG, Carman GM, Waggoner DW, Brindley DN: Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters. Biochem J (1999) 340:677-686.
45. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G: Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem (2002) 277:21197-21206.
46. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 158:227-233. Lysophospholipase D purified from bovine serum appears to be identical to the 'autocrine motility factor, autotaxin, providing conclusive evidence that the biological effects of recombinant ATX/lysoPLD are mediated by newly generated LPA.
47. Moolenaar WH: Lysophospholipids in the limelight: Autotaxin takes center stage. J Cell Biol (2002) 158:197-199.
48. Brindley DN, Waggoner DW: Mammalian lipid phosphate phosphohydrolases. J Biol Chem (1998) 273:24281-24284.
49. Hooks SB, Santos WL, Im DS, Heise CE, Macdonald TL, Lynch KR: Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edgreceptor independent. J Biol Chem (2001) 276:4611-4621.
50. 2+ control lysophosphatidate signaling through EDG-2 receptors. J Biol Chem (2000) 275:27520-27530.
51. Pilquil C, Ling ZC, Singh I, Buri K, Zhang QX, Brindley DN: Co-ordinate regulation of growth factor receptors and lipid phosphate phosphatase-1 controls cell activation by exogenous lysophosphatidate. Biochem Soc Trans (2001) 29:825-830.
52. Zheng Y, Kong Y, Goetzl EJ: Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol (2001) 166:2317-2322.
53. Moolenaar WH: Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem (1995) 270:12949-12952. A good minireview of LPA, explaining its function as an intercellular messenger.
54. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A, Hanahan DJ: Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta (1999) 1440:194-204.
55. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A et al: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res (1995) 1:1223-1232.
56. Liliom K, Guan Z, Tseng JL, Desiderio DM, Tigyi G, Watsky MA: Growth factor-like phospholipids generated after corneal injury. Am J Physiol (1998) 274:C1065-C1074.
57. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K: Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structureactivity relationship of cloned LPA receptors. FEBS Lett (2000) 478:159-165.
58. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, Tigyi G: International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev (2002) 54:265-269. A rational nomenclature for LPA and S1P receptors is proposed in this review, which is consistent with the International Union of Pharmacology guidelines.
59. An S, Bleu T, Hallmark OG, Goetzl EJ: Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem (1998) 273:7906-7910. This study contributed to defining novel subtypes of LPA receptors, and demonstrated that EDG-4 was a novel subtype of LPA, with different tissue distribution to EDG-2.
60. Weiner JA, Hecht JH, Chun J: Lysophosphatidic acid receptor gene vzg-1/Ip/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol (1998) 398:587-598.
61. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K: Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem (1999) 274:27776-27785.
62. An S, Goetzl EJ, Lee H: Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. J Cell Biochem Suppl (1998) 31:147-157. This review summarizes the signaling pathways that are critical for cellular responses to LPA and S1P, and comments on the progress in the molecular biological analyses of the EDG receptors.
63. Weiner JA, Fukushima N, Contos JJ, Scherer SS, Chun J: Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci (2001) 21:7069-7078.
64. Kou R, Igarashi J, Michel T: Lysophosphatidic acid and receptor-mediated activation of endothelial nitric-oxide synthase. Biochemistry (2002) 41:4982-4988.
65. Hannun YA, Luberto C, Argraves KM: Enzymes of sphingolipid metabolism: From modular to integrative signaling. Biochemistry (2001) 40:4893-4903.
66. Kabarowski JH, Zhu K, Le LQ, Witte ON, Xu Y: Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science (2001) 293:702-705.
67. Le LQ, Kabarowski JH, Weng Z, Satterthwaite AB, Harvill ET, Jensen ER, Miller JF, Witte ON: Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity (2001) 14:561-571.
68. Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, Okado H, Toh H, Ito K, Miyamoto T, Shimizu T: Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature (1991) 349:342-346.
69. Honda Z, Ishii S, Shimizu T: Platelet-activating factor receptor. J Biochem (Tokyo) (2002) 131:773-779.
70. Ishii S, Shimizu T: Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res (2000) 39:41-82.
71. 2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers. Prostaglandins Leukot Essent Fatty Acids (1999) 61:65-82.
72. Southall MD, Isenberg JS, Nakshatri H, Yi Q, Pei Y, Spandau DF, Travers JB: The platelet-activating factor receptor protects epidermal cells from tumor necrosis factor (TNF)α and TNF-related apoptosis-inducing ligand-induced apoptosis through an NF-κB-dependent process. J Biol Chem (2001) 276:45548-45554.
73. Walterscheid JP, Ullrich SE, Nghiem DX: Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med (2002) 195:171-179.
74. Funk CD: Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science (2001) 294:1871-1875.
75. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, Ichikawa A, Narumiya S: The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest (2002) 109:883-893.
76. Tilley SL, Coffman TM, Koller BH: Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest (2001) 108:15-23.
77. 2 EP-receptor mediates pain perception and regulates blood pressure. J Clin Invest (2001) 107:325-331.
78. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature (2000) 405:421-424.
79. Wahli W: Peroxisome proliferator-activated receptors (PPARs): From metabolic control to epidermal wound healing. Swiss Med Wkly (2002) 132:83-91.
80. Klappacher GW, Glass CK: Roles of peroxisome proliferator-activated receptor γ in lipid homeostasis and inflammatory responses of macrophages. Curr Opin Lipidol (2002) 13:305-312.
81. Rosen ED, Spiegelman BM: PPARγ: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem (2001) 276:37731-37734.
82. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, Palmer CN: The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J Biol Chem (2001) 276:44258-44265.
83. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE et al: A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA (2001) 98:5306-5311.
84. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS: Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists. J Biol Chem (2001) 276:25651-25653.
85. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 93:241-252.
86. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab (2001) 86:3452-3456.
87. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D et al: Impaired skin wound healing in peroxisome proliferator-activated receptor PPARα and PPARβ mutant mice. J Cell Biol (2001) 154:799-814.
88. Park BH, Vogelstein B, Kinzler KW: Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA (2001) 98:2598-2603.
89. Sugiura T, Waku K: 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids (2000) 108:89-106.
90. Mechoulam R, Fride E, DiMarzoV: Endocannabinoids. Eur J Pharmacol (1998) 359:1-18.
91. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R: 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB-receptor. Proc Natl Acad Sci USA (2001) 98:3662-3665.
92. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561-564.
93. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
94. Childers SR, Breivogel CS: Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend (1998) 51:173-187.
95. Breivogel CS, Griffin G, Di Marzo V, Martin BR: Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 60:155-163.
96. Pertwee RG: Pharmacology of cannabinoid receptor ligands. Curr Med Chem (1999) 6:635-664.
97. Craib SJ, Ellington HC, Pertwee RG, Ross RA: A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol (2001) 134:30-37.
98. Pertwee RG, Ross RA: Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids (2002) 66:101-121.
99. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR: Highly selective CB, cannaboid receptor ligands and novel CBVR, vanilloid receptor 'hybrid' ligands. Biochem Biophys Res Commun (2001) 281:444-451.
100. Derkinderen P, Ledent C, Parmentier M, Girault JA: Cannabinoids activate p38 mitogen-activated protein kinases through CB, receptors in hippocampus. J Neurochem (2001) 77:957-960.
101. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 400:452-457.
102. Maingret F, Patel AJ, Lazdunski M, Honore E: The endocannabinoid anandamide is a direct and selective blocker of the background K-channel TASK-1. EMBO J (2001) 20:47-54.
103. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, Fernandez-Ruiz JJ, Hansen HS: Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem (2001) 78:1415-1427.
104. van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K: Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci (2001) 21:8765-8771.
105. Hansen HH, Ikonomidou C, Bittigau P, Hansen SH, Hansen HS: Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J Neurochem (2001) 76:39-46.
106. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 413:527-531.
107. Schabitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D: Release of fatty acid amides in a patient with hemispheric stroke: A microdialysis study. Stroke (2002) 33:2112-2114.
108. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 215:89-97.
109. Sugiura T, Kobayashi Y, Oka S, Waku K: Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids (2002) 66:173-192.
110. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir Al, Chambers JK, Randall AD, Davis JB: The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol (2000) 129:227-230.
111. Savinainen JR, Jarvinen T, Laine K, Laitinen JT: Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB, receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol (2001) 134:664-672.
112. Sugiura T, Waku K: Cannabinoid receptors and their endogenous ligands. J Biochem (Tokyo) (2002) 132:7-12.
113. Kreitzer AC, Regehr WG: Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 29:717-727.
114. Wilson RI, Nicoll RA: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410:588-592.
115. Ohno-Shosaku T, Maejima T, Kano M: Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron (2001) 29:729-738.
116. 1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem (2002) 82:154-158.
117. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai J, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptinregulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410:822-825.
118. Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A, Berrebi-Bertrand I: EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol (2001) 33:1589-1606.
119. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, Milstien S, Spiegel S: Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science (2001) 291:1800-1803.
120. Rosenfeldt HM, Hobson JP, Maceyka M, Olivera A, Nava VE, Milstien S, Spiegel S: EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. FASEB J (2001) 15:2649-2659.
121. Alderton F, Rakhit S, Kong KC, Palmer T, Sambi B, Pyne S, Pyne NJ: Tethering of the platelet-derived growth factor β receptor to G-protein-coupled receptors. A novel platform for integrative signaling by these receptor classes in mammalian cells. J Biol Chem (2001) 276:28578-28585.
122. MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR, Anderson KJ, Roper SN, Lee N: An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci (2001) 14:203-209.
123. B3/EDG-3. J Biol Chem (2001) 276:33697-33704.
124. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Ha T: Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 99:301-312.
125. Paik JH, Chae Ss, Lee MJ, Thangada S, Hla T: Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rhodependent activation of αvβ3- and β1-containing integrins. J Biol Chem (2001) 276:11830-11837.
126. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J: Requirement for the IpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA (2000) 97:13384-13389.
127. Yang AH, Ishii I, Chun J: In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim Biophys Acta (2002) 1582:197-203.
128. 2. Mol Cell Biol (2002) in press.
129. Moolenaar WH: Development of our current understanding of bioactive lysophospholipids. Ann NY Acad Sci (2000) 905:1-10.
130. Tigyi G, Dyer DL, Miledi R: Lysophosphatidic acid possesses dual action in cell proliferation. Proc Natl Acad Sci USA (1994) 91:1908-1912.
131. Pages C, Daviaud D, An S, Krief S, Lafontan M, Valet P, Saulnier-Blache JS: Endothelial differentiation gene-2 receptor is involved in lysophosphatidic acid-dependent control of 3T3F442A preadipocyte proliferation and spreading. J Biol Chem (2001) 276:11599-11605.
132. Sautin YY, Crawford JM, Svetlov SI: Enhancement of survival by LPA via Erk1/Erk2 and P-3-kinase/Akt pathways in a murine hepatocyte cell line. Am J Physiology Cell Physiology (2001) 281:C2010-C2019.
133. Pebay A, Torrens Y, Toutant M, Cordier J, Glowinski J, Tence M: Pleiotropic effects of lysophosphatidic acid on striatal astrocytes. Glia (1999) 28:25-33.
134. Pebay A, Toutant M, Premont J, Calvo CF, Venance L, Cordier J, Glowinski J, Tence M: Sphingosine-1-phosphate induces proliferation of astrocytes: Regulation by intracellular signalling cascades. Eur J Neurosci (2001) 13:2067-2076.
135. Gennero I, Fauvel J, Nieto M, Cariven C, Gaits F, Briand-Mesange F, Chap H, Salles JP: Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolysis on mesangial cells cultured at low cell density. J Biol Chem (2002) 277:12724-12734.
136. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S: Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature (1996) 381:800-803.
137. Kluk MJ, Hla T: Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res (2001) 89:496-502.
138. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D: Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest (2001) 108:689-701.
139. Cross MJ, Roberts S, Ridley AJ, Hodgkin MN, Stewart A, Claesson-Welsh L, Wakelam MJ: Stimulation of actin stress fibre formation mediated by activation of phospholipase D. Curr Biol (1996) 6:588-597.
140. 2+ in human endothelial cells. J Physiol (1997) 504:315-326.
141. Schulze C, Smales C, Rubin LL, Staddon JM: Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J Neurochem (1997) 68:991-1000.
142. Alexander JS, Patton WF, Christman BW, Cuiper LL, Haselton FR: Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro. Am J Physiol (1998) 274:H115-H122.
143. English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN, Garcia JG: Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res (1999) 8:627-634.
144. Minnear FL, Patil S, Bell D, Gainor JP, Morton CA: Platelet lipid(s) bound to albumin increases endothelial electrical resistance: Mimicked by LPA. Am J Physiol Lung Cell Mol Physiol (2001) 281:L1337-L1344.
145. Lum H: Lysophospholipids in the regulation of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol (2001) 281:L1335-L1336.
146. Budnik LT, Mukhopadhyay AK: The protein kinase C is redistributed to the nucleus in lysophosphatidic acid stimulated theca lutein cells. Biol Reprod (2001) 64 (Suppl):255.
147. Gogarten W, Emala CW, Lindeman KS, Hirshman CA: Oxytocin and lysophosphatidic acid induce stress fiber formation in human myometrial cells via a pathway involving Rho-kinase. Biol Reprod (2001) 65:401-406.
148. 1 regulation. Biol Reprod (2000) 63:1271-1277.
149. Budnik LT, Mukhopadhyay AK: Lysophosphatidic acid and its role in reproduction. Biol Reprod (2002) 66:859-865.
150. Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP: Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: Sildenafil and papaverin generate inhibition. Prostate (2002) 51:50-58.
151. Ediger TL, Danforth BL, Toews ML: Lysophosphatidic acid upregulates the epidermal growth factor receptor in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2002) 282:L91-L98.
152. Amishima M, Munakata M, Nasuhara Y, Sato A, Takahashi T, Homma Y, Kawakami Y: Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Crit Care Med (1998) 157:1907-1912.
153. Puddicombe SM, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST, Davies DE: Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J (2000) 14:1362-1374.
154. Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP, Kane SA, Peters SP, Penn RB, Spiegel S, Panettieri RA Jr: Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J (2001) 15:1212-1214.
155. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S: Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol (1998) 9:437-442.
156. Shen Z, Wu M, Elson P, Kennedy AW, Belinson J, Casey G, Xu Y: Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol (2001) 83:25-30.
157. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G: Lysophosphafidic acid as a potential biomarker for ovarian and other gynecologic cancers. J Am Med Assoc (1998) 280:719-723.
158. Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM, Bonfrer JM, Bais E, Moolenaar WH, Tigyi G: Plasma lysophosphatidic acid concentration and ovarian cancer. J Am Med Assoc (2002) 287:3081-3082.
159. Schulte KM, Beyer A, Kohrer K, Oberhauser S, Roher HD: Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: Over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer (2001) 92:249-256.
160. Lynch KR, Macdonald TL: Structure-activity relationships of lysophosphatidic acid analogs. Biochim Biophys Acta (2002) 1582:289-294.
161. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang Da, Baker DL, Bautista D, Paill AL, Tigyi G: Short-chain phosphatidates are subtype-selective
162. 3 receptor antagonist. Mol Pharmacol (2001) 60:1173-1180. This paper reports results on derivatives of N-acyl ethanolamide phosphate that display subtype selective agonist and antagonist properties for the endothelial differentiation gene family of LPA receptors.